Failure of vitamin B6 to reverse the l-dopa effect in patients on a dopa decarboxylase inhibitor
Failure of vitamin B6 to reverse the l-dopa effect in patients on a dopa decarboxylase inhibitor
复制标题
维生素 B6 未能逆转服用多巴脱羧酶抑制剂的患者的左旋多巴效应
DOI：
10.1136/jnnp.34.6.682
复制
发表时间：
1971
影响因子：
11
通讯作者：
D. Shenker
中科院分区：
文献类型：
--
作者：
H. Klawans;S. Ringel;D. Shenker
7例既往服用L-多巴的帕金森综合征患者接受L-多巴和α-甲基多巴肼(一种多巴脱羧酶抑制剂)的方案治疗。其中两名患者之前曾在服用吡哆醇时表现出明显的L-多巴改善的临床恶化。接受甲基多巴肼治疗的七名患者中，没有一人在服用吡哆醇后病情有任何变化。在同时接受L-多巴和外周多巴脱羧酶抑制剂治疗的患者中，维生素B6未能逆转L-多巴的临床效果，这表明维生素B6诱导的L-多巴效应的逆转是由于中枢神经系统外的多巴脱羧酶活性增加所致。
Seven patients with Parkinsonism previously on l-dopa were placed on a regimen of l-dopa and alpha methyl dopa hydrazine (a dopa decarboxylase inhibitor). Two of these patients had previously shown marked clinical deterioration of the l-dopa improvement when given pyridoxine. None of the seven patients receiving alpha methyl dopa hydrazine demonstrated any change in their condition when given pyridoxine. The failure of vitamin B6 to reverse the clinical effect of l-dopa in patients receiving both l-dopa and a peripheral dopa decarboxylase inhibitor suggests that reversal of the l-dopa effect induced by vitamin B6 is due to increasing the activity of the enzyme dopa decarboxylase outside the central nervous system.